Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 13/20 | 0.49 |
| ▸ | KIT | P10721 | 7/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | HCK | P08631 | 1/20 | 0.41 |
| ▸ | FGR | P09769 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CSK | P41240 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | BMX | P51813 | 1/20 | 0.41 |
| ▸ | SRMS | Q9H3Y6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323183 | 0.89 | CSF1R (0.41) | CSF1RKITDDR1 | |
| SCHEMBL15907294 | 0.81 | LCK (0.44) | CSF1RKITDDR1DDR2ABL1 | |
| SCHEMBL15907291 | 0.79 | KIT (0.62) | KITABL1SRC | |
| SCHEMBL15907249 | 0.79 | KIT (0.48) | CSF1RKITDDR1ABL1 | |
| SCHEMBL18323165 | 0.78 | MAPT (0.35) | CSF1RKIT | |
| SCHEMBL15907158 | 0.77 | KIT (0.55) | CSF1RKITDDR1DDR2ABL1 | |
| SCHEMBL15907289 | 0.77 | CSF1R (0.43) | CSF1RKITDDR1DDR2ABL1 | |
| SCHEMBL15907241 | 0.74 | PLAU (0.39) | CSF1RABL1 | |
| SCHEMBL18323163 | 0.74 | CSF1R (0.43) | CSF1RKITABL1LCKFYN | |
| SCHEMBL15907302 | 0.72 | IKBKB (0.46) | CSF1RABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | CSF1R 1848/4885KIT 577/4885DDR1 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.